Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by Nir Paran and Hadas Tamir.
Nir Paran
Connection Strength
0.462
Hadas Tamir
  1. The neutralization potency of anti-SARS-CoV-2 therapeutic human monoclonal antibodies is retained against viral variants. Cell Rep. 2021 09 07; 36(10):109679.
    View in: PubMed
    Score: 0.060
  2. SARS-CoV-2 uses a multipronged strategy to impede host protein synthesis. Nature. 2021 06; 594(7862):240-245.
    View in: PubMed
    Score: 0.059
  3. Glucosylceramide synthase inhibitors prevent replication of SARS-CoV-2 and influenza virus. J Biol Chem. 2021 Jan-Jun; 296:100470.
    View in: PubMed
    Score: 0.058
  4. Design of SARS-CoV-2 hFc-Conjugated Receptor-Binding Domain mRNA Vaccine Delivered via Lipid Nanoparticles. ACS Nano. 2021 06 22; 15(6):9627-9637.
    View in: PubMed
    Score: 0.058
  5. A single dose of recombinant VSV-?G-spike vaccine provides protection against SARS-CoV-2 challenge. Nat Commun. 2020 12 16; 11(1):6402.
    View in: PubMed
    Score: 0.057
  6. Detection and infectivity potential of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) environmental contamination in isolation units and quarantine facilities. Clin Microbiol Infect. 2020 Dec; 26(12):1658-1662.
    View in: PubMed
    Score: 0.056
  7. The coding capacity of SARS-CoV-2. Nature. 2021 01; 589(7840):125-130.
    View in: PubMed
    Score: 0.056
  8. A panel of human neutralizing mAbs targeting SARS-CoV-2 spike at multiple epitopes. Nat Commun. 2020 08 27; 11(1):4303.
    View in: PubMed
    Score: 0.056
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.